Male exposure in ewes decreased the content of <i>Tac2</i> mRNA in the rostral ARC. by Julie-Ann P. De Bond (383668)

Local injection of p29 alleviates the reduction in myofiber size by restoration of the decreased numbers of satellite cells. by Yutaka Ohsawa (587120)

Activation of mitoK_ATP channels decreased the latency time of the transjunctional currents in slice. by Jiangping Wang (281901)

“…The control experiment is shown in (<b>A1</b>). (<b>B</b>) Bar graph shows that at 6 min after exposure to DIZ, the latency time was decreased by 50% with an average of 234.54±34.43 µs (n = 13). …”

Pirfenidone stabilized the mitochondrial membrane potential (MMP) and decreased intracellular ROS in renal proximal tubular cells. by Jun-Feng Chen (494741)

Ppk1 levels are not affected by decreasing dendrite arbor size but are reduced when dendrite length increases. by Josephine W. Mitchell (17364781)

Tg2576 mice treated with OG showed markedly increased α-secretase cleavage of APP and significantly decreased levels of Aβ generation. by She-Qing Zhang (446556)

Anti-CXCR3 group decreased number of specific CD8⁺ T cells as well as polyfunctionality after infection with <i>T</i>. <i>cruzi</i>. by Camila Pontes Ferreira (6194006)

Decreased E/I synapse ratio and loss of cortico-LA synaptic plasticity in the absence of coronin 1. by Rajesh Jayachandran (542641)

“…Scale bar, 2 microns. Data shown are mean values ± SD, <i>p</i><0.01. (C) Hippocampal neurons were labeled using anti-vGLUT1 and anti-vGAT antibodies, followed by Alex Fluor 488 or 568 labeled secondary antibodies, respectively. …”

a-f. PSP significantly decreased NP-specific IgM responses at days 4 and 21 compared to ACACIA. by Bhagwant Kaur Sekhon (847697)

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

“…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Pharmacologically induced torpor by 5′-AMP does not decrease platelet count despite decreased body temperature. by Edwin L. de Vrij (550179)

“…<p>A) Pharmacologically induced torpor by 5′-AMP in mice does not decrease platelet count during torpor and shows an increase upon arousal. …”

Structure of P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Fig 5 - by Jacob C. Jentzer (4746999)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)